231-OR: Dexcom G6 Pro Accuracy and Reproducibility in the Intensive Care Unit

Le résumé fourni par la source

Introduction and Objective: To evaluate the accuracy and reproducibility of the Dexcom G6 Pro sensor in a hospital ICU setting in persons with diabetes or hyperglycemia in the absence of diabetes. Methods: At 5 U.S. academic centers, 9,121 glucose levels obtained with a Dexcom G6 Pro sensor were compared with venous or capillary blood glucose (BG) measurements in 130 adults hospitalized in the ICU (95 with diabetes and 35 with hyperglycemia without diabetes), 124 of whom simultaneously wore 2 sensors. Results: The median relative absolute difference (RAD) was 19% comparing CGM and BG measurements, with 41% of CGM values either within 15% or 15 mg/dL of the corresponding BG value. CGM values were consistency higher than BG values across the entire glucose range, with a median difference (CGM minus BGM) of 25 mg/dL (Table). Median RAD and median difference varied little according to day of sensor wear. For 186,648 paired CGM values from 2 simultaneously worn sensors, median RAD was 11%. Conclusion: In the ICU setting, the G6 Pro sensor tended to be biased high and the median RAD was greater than expected based on prior outpatient studies. It cannot be determined whether this bias and reduced accuracy is a function of the specific sensor or related to the ICU setting. Disclosure J. Ullal: None. C. Spanbauer: None. J.H. Chao: Research Support; Dexcom, Inc. F.J. Pasquel: Consultant; Insulet Corporation. Research Support; Novo Nordisk, Dexcom, Inc., Ideal Medical Technologies, Tandem Diabetes Care, Inc, Insulet Corporation. Consultant; Dexcom, Inc. M.S. Jones: None. C.C. Low Wang: Research Support; Dexcom, Inc., Virta Health Corp. J.B. Buse: Other Relationship; Corcept Therapeutics, Dexcom, Inc., Novo Nordisk. Consultant; Altimmune Inc, Amgen Inc, ApStem, Aqua Medical, AstraZeneca, Boehringer-Ingelheim, CeQur, Eli Lilly and Company, embecta, GentiBio. Other Relationship; Glyscend Therapeutics. Consultant; Insulet Corporation, Medtronic. Other Relationship; Mellitus Health. Consultant; Metsera. Other Relationship; Pendulum Therapeutics, Praetego, Stability Health. Consultant; Tandem Diabetes Care, Inc, TERNS Pharmaceuticals, Vertex Pharmaceuticals Incorporated, Zealand Pharma A/S. B. Draznin: None. J. Sibayan: None. C. Kollman: Research Support; Dexcom, Inc., Insulet Corporation, MannKind Corporation, Breakthrough T1D (formerly JDRF), Capillary Biomedical, Inc, Hemsley Charitable Trust, National Institute of Diabetes and Digestive and Kidney Diseases, Tandem Diabetes Care, Inc. R.W. Beck: Research Support; Insulet Corporation. Consultant; Insulet Corporation. Research Support; Tandem Diabetes Care, Inc, Beta Bionics, Inc, Dexcom, Inc., Bigfoot Biomedical, Inc, Abbott, embecta, Sequel Med Tech, MannKind Corporation. Consultant; Novo Nordisk, Vertex Pharmaceuticals Incorporated, Hagar, Ypsomed AG, Zucara Therapeutics, Abata Therapeutics, Eli Lilly and Company. I.B. Hirsch: Research Support; Dexcom, Inc., Tandem Diabetes Care, Inc, MannKind Corporation. Consultant; Abbott, Roche Diabetes Care, Hagar. Funding Dexcom, Inc

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.